Fatigue, symptom burden, and health-related quality of life in patients with myelodysplastic syndrome, aplastic anemia, and paroxysmal nocturnal hemoglobinuria-Reference-Cited by-同舟云学术

Fatigue, symptom burden, and health-related quality of life in patients with myelodysplastic syndrome, aplastic anemia, and paroxysmal nocturnal hemoglobinuria

Published:2019-01-11 Issue:2 Volume:8 Page:543-553
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Escalante Carmen P.¹^ORCID,Chisolm Stephanie²,Song Juhee³,Richardson Marsha¹,Salkeld Ellen⁴,Aoki Etsuko¹,Garcia-Manero Guillermo⁵

Affiliation:

1. Department of General Internal Medicine; The University of Texas MD Anderson Cancer Center; Houston Texas

2. Bladder Cancer Advocacy Network; Bethesda Maryland

3. Department of Biostatistics; The University of Texas MD Anderson Cancer Center; Houston Texas

4. Aplastic Anemia and MDS International Foundation; Bethesda Maryland

5. Department of Leukemia; The University of Texas MD Anderson Cancer Center; Houston Texas

Funder

National Cancer Institute

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cam4.1953/fullpdf

Reference32 articles.

1. Aplastic Anemia & MDS International Foundation (AA&MDSIF): bone marrow failure disease scientific symposium 2012;Savage;Leuk Res,2013

2. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes;Vardiman;Blood,2009

3. Myelodysplastic syndromes: incidence and survival in the United States;Ma;Cancer,2007

5. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs;Rollison;Blood,2008

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Momelotinib in myelofibrosis and beyond: a comprehensive review of therapeutic insights in hematologic malignancies;Discover Oncology;2024-08-27

2. Patient-reported outcomes and daily activity assessed with a digital wearable device in patients with paroxysmal nocturnal hemoglobinuria treated with ravulizumab: REVEAL, a prospective, observational study;Health and Quality of Life Outcomes;2024-08-09

3. A latent profile analysis of health-related quality of life in patients with aplastic anemia;2024-08-09

4. Pharmacokinetics, pharmacodynamics, efficacy, and safety of ravulizumab in pediatric paroxysmal nocturnal hemoglobinuria;Blood Advances;2024-05-31